StockData
MoonLake Immunotherapeutics logo

MoonLake Immunotherapeutics (MLTX) stock

MLTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 1/30
$12.50−0.37 (-2.87%)

Close on Nov 13, 2026Market cap $1.06BP/E –Yield –

MoonLake Immunotherapeutics total assets

Total assets on the balance sheet at the end of each period.

MoonLake Immunotherapeutics's total assets was $540.72M at Sep 30, 2026. For fiscal 2025 it was $424.43M, down 11.2% from the year before. The highest annual figure on record is $526.54M in fiscal 2023.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$424.43M-11.2%
FY2024Dec 31, 2024$477.93M-9.2%
FY2023Dec 31, 2023$526.54M+585.2%
FY2022Dec 31, 2022$76.84M+693.6%
FY2021Dec 31, 2021$9.68M-91.7%
FY2020Dec 31, 2020$116.63M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$540.72M+30.5%
Q2 FY2026Jun 30, 2026$573.95M+24.7%
Q1 FY2026Mar 31, 2026$400.37M-21.7%
Q4 FY2025Dec 31, 2025$424.43M-11.2%
Q3 FY2025Sep 30, 2025$414.34M-20.0%
Q2 FY2025Jun 30, 2025$460.10M-15.6%
Q1 FY2025Mar 31, 2025$511.26M-9.4%
Q4 FY2024Dec 31, 2024$477.93M-9.2%
Q3 FY2024Sep 30, 2024$518.21M+3.6%
Q2 FY2024Jun 30, 2024$544.88M+7.6%
Q1 FY2024Mar 31, 2024$564.12M+744.5%
Q4 FY2023Dec 31, 2023$526.54M+585.2%
Q3 FY2023Sep 30, 2023$500.22M+464.6%
Q2 FY2023Jun 30, 2023$506.62M+414.7%
Q1 FY2023Mar 31, 2023$66.80M-71.1%
Q4 FY2022Dec 31, 2022$76.84M+693.6%
Q3 FY2022Sep 30, 2022$88.59M-23.8%
Q2 FY2022Jun 30, 2022$98.43M-15.4%
Q1 FY2022Mar 31, 2022$231.21M+98.5%
Q4 FY2021Dec 31, 2021$9.68M-91.7%
Q3 FY2021Sep 30, 2021$116.25M+70993.5%
Q2 FY2021Jun 30, 2021$116.37M–
Q1 FY2021Mar 31, 2021$116.49M–
Q4 FY2020Dec 31, 2020$116.63M–
Q3 FY2020Sep 30, 2020$163.51K–

More MoonLake Immunotherapeutics figures

See a number that looks wrong?